Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | MGLL | Q99685 | 9/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.30 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.30 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.30 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.30 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7938647 | 0.78 | MEN1 (0.41) | MGLLALDH1A1TSHRACHE | |
| SCHEMBL12153360 | 0.77 | MGLL (0.30) | MGLL | |
| SCHEMBL2826280 | 0.77 | MGLL (0.30) | MGLL | |
| SCHEMBL13533087 | 0.77 | MGLL (0.32) | MGLL | |
| SCHEMBL15264555 | 0.76 | TSHR (0.35) | RAB9AALDH1A1TSHRCHRM2CHRM4 | |
| SCHEMBL27331623 | 0.76 | MT-CO2 (0.35) | — | |
| SCHEMBL9002612 | 0.75 | ACHE (0.40) | RAB9AMGLLALDH1A1TSHRACHE | |
| SCHEMBL18510166 | 0.75 | GLA (0.41) | MGLLGLAALDH1A1TSHR | |
| SCHEMBL30779753 | 0.75 | GLA (0.41) | MGLLGLAALDH1A1TSHR | |
| SCHEMBL30699 | 0.75 | GLA (0.41) | MGLLGLAALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150080364-A1 | CARBAMATE COMPOUNDS AND OF MAKING AND USING SAME | ABIDE THERAPEUTICS, INC. (US) | 2015-03-19 | — | — | US | claimed |
| EP-2828253-A1 | CARBAMATE COMPOUNDS AND OF MAKING AND USING SAME | Abide Therapeutics, Inc. (US) | 2015-01-28 | — | — | EP | claimed |
| WO-2013142307-A1 | CARBAMATE COMPOUNDS AND OF MAKING AND USING SAME | ABIDE THERAPEUTICS (US) | 2013-09-26 | — | — | WO | claimed |
| US-6245478-B1 | Resist composition | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2001-06-12 | — | — | US | claimed |
| WO-2020200880-A1 | COMPOUNDS AND CONJUGATES THEREOF | MEDIMMUNE LIMITED (GB) | 2020-10-08 | — | — | WO | disclosed |
| US-9567302-B2 | Carbamate compounds and of making and using same | ABIDE THERAPEUTICS, INC. (US) | 2017-02-14 | — | — | US | disclosed |
| US-9567302-B2 | Carbamate compounds and of making and using same | ABIDE THERAPEUTICS, INC. (US) | 2017-02-14 | — | — | US | disclosed |
| US-9567302-B2 | Carbamate compounds and of making and using same | ABIDE THERAPEUTICS, INC. (US) | 2017-02-14 | — | — | US | disclosed |
| US-20150080364-A1 | CARBAMATE COMPOUNDS AND OF MAKING AND USING SAME | ABIDE THERAPEUTICS, INC. (US) | 2015-03-19 | — | — | US | disclosed |
| US-20150080364-A1 | CARBAMATE COMPOUNDS AND OF MAKING AND USING SAME | ABIDE THERAPEUTICS, INC. (US) | 2015-03-19 | — | — | US | disclosed |
| US-20150080364-A1 | CARBAMATE COMPOUNDS AND OF MAKING AND USING SAME | ABIDE THERAPEUTICS, INC. (US) | 2015-03-19 | — | — | US | disclosed |
| EP-2828253-A1 | CARBAMATE COMPOUNDS AND OF MAKING AND USING SAME | Abide Therapeutics, Inc. (US) | 2015-01-28 | — | — | EP | disclosed |
| WO-2013142307-A1 | CARBAMATE COMPOUNDS AND OF MAKING AND USING SAME | ABIDE THERAPEUTICS (US) | 2013-09-26 | — | — | WO | disclosed |
| WO-2013142307-A1 | CARBAMATE COMPOUNDS AND OF MAKING AND USING SAME | ABIDE THERAPEUTICS (US) | 2013-09-26 | — | — | WO | disclosed |
| US-20110159519-A1 | OPTICAL BIOSENSORS | CARNEGIE MELLON UNIVERSITY (US) | 2011-06-30 | — | — | US | disclosed |
| US-6245478-B1 | Resist composition | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2001-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110159519-A1 | OPTICAL BIOSENSORS | NCS1, MCU, LPO | RAB9A 1725/4885MGLL 832/4885GLA 761/4885 |
| US-20150080364-A1 | CARBAMATE COMPOUNDS AND OF MAKING AND USING SAME | CPS1, FABP4, VHL | RAB9A 2771/4885MGLL 558/4885GLA 1946/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.